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ABSTRACT 74 
 75 
Background: Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of 76 
papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and 77 
genetic level. MiRNA deregulation was extensively studied in PTCs and FTCs; however, very 78 
limited information is available for FVPTC. The aim of this study was to assess miRNA 79 
expression in FVPTC with the most comprehensive miRNA array panel and to correlate it with 80 
the clinicopathological data.  81 
Methods: Forty-four papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and 8 normal 82 
thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray 83 
Assays on the ABI 7900 platform (Life Technologies). In addition, an independent set of 61 84 
tumor and normal samples was studied for expression of novel miRNA markers detected in this 85 
study. 86 
Results: Overall, the miRNA expression profile demonstrated similar trends between FVPTC 87 
and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than 88 
5 (up/down) including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -89 
222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the 90 
levels of miRNA expression were different between these tumor types and some miRNAs were 91 
uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised 92 
hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large 93 
independent set of follicular cell derived neoplasms and benign nodules and demonstrated 94 
specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated 95 
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with an adverse outcome in FVPTC patients by a Kaplan Meier (p<0.05) and multivariate Cox 96 
regression analysis (p<0.05).  97 
Conclusions: Despite high similarity in miRNA expression between FVPTC and classic PTC, 98 
several miRNAs were uniquely expressed in each tumor type supporting their histopathologic 99 
differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel 100 
marker of papillary thyroid carcinoma and miR-181a-2-3p and miR-99b-3p can predict relapse-101 
free survival in patients with FVPTC thus potentially providing important diagnostic and 102 
predictive value. 103 
104 
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INTRODUCTION 105 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy (1). It 106 
comprises several variants that are classified on the basis of their morphologic features. 107 
Follicular variant of papillary carcinoma (FVPTC) is the most common variant and diagnosed in 108 
about 15-30% of PTC (1, 2). Historically, all thyroid tumors with follicular growth were 109 
diagnosed as follicular thyroid carcinomas (FTC). The first histologic description of FVPTC 110 
occurred in 1960, but nevertheless, it was not until 1977 when this entity was further 111 
characterized in a landmarkpaper by Chem and Rosai and found its way into daily clinical 112 
practice (2, 3). Since then, the scientific debate about this remarkable entity is ongoing. While 113 
these tumors have characteristic nuclear features of PTC, they demonstrate a follicular growth 114 
pattern and complete lack of well-formed papillae (2). Moreover, the metastatic pattern of these 115 
tumors often resembles classic PTC with cervical lymph node metastasis but, some cases may 116 
demonstrate distant hematologic metastases, a finding more common in FTC (4). 117 
 118 
At the molecular level, FVPTCs also appear as an entity located between PTC and FTC. It 119 
frequently harbors RAS mutations and the PAX8/PPARγ rearrangement can also be detected; both 120 
events are common in follicular tumors and are rare in classic PTC (5). On the other hand, it may 121 
have BRAF gene mutations – but, in contrast to the usual BRAF V600E found in classic PTC, 122 
FVPTC have a distinct BRAF K601E mutation. BRAF K601E is very rare in FTC and was only 123 
described in one case in previous publications (6, 7). In addition, the overall gene expression 124 
profile in FVPTC is distinct from classic PTC, underlining these differences (8, 9). In summary, 125 
FVPTC shares features of classic PTC and FTC on the morphological, genetic and prognostic 126 
level. 127 
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 128 
MicroRNAs (miRNAs) are small endogenous, non-coding RNAs that regulate gene expression 129 
in practically every major cellular function, and as a consequence, deregulated miRNAs have 130 
been linked to a variety of different cancers throughout the human body including thyroid 131 
carcinomas (10, 11). Thyroid tumors encompass different miRNA profiles depending on the 132 
histological subtype (12, 13). Some miRNAs like miR-221 or -222 have been reported in both 133 
classic PTC and FTC, while others like miR-146b and miR-31 have been reported in PTC only 134 
(14).  135 
The goal of this study was to examine miRNA expression in a large series of FVPTC using the 136 
most comprehensive miRNA profile available and correlate it with the clinicopathological data.  137 
 138 
MATERIAL AND METHODS 139 
 140 
Tissue samples and patient characteristics. For miRNA expression profiling, 52 neoplastic 141 
and non-neoplastic formalin-fixed paraffin embedded (FFPE) thyroid tissue samples were 142 
analyzed including 17 FVPTC, 27 classic PTC, and 8 normal thyroid tissues. The tissues were 143 
received from the University Hospital Zürich, Switzerland and surrounding pathology institutes.  144 
Two groups of patients were included in this study: 1) Patients with an adverse clinical outcome 145 
(ACO) defined as recurrent tumor relapse or patient death and 2) control group of patients that 146 
had a normal (favorable) outcome without tumor relapse or death. For the ACO group, the 147 
records were searched at the Department of Nuclear Medicine, Canton Zürich for thyroid 148 
carcinoma cases that had been operated between 1990 and 2006 and had one of the following 149 
characteristics: tumor relapse after first radioiodine therapy, distant metastases or tumor-150 
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9 
associated death. All patients from this group were matched by age, stage and sex to the group of 151 
patients with a favorable outcome. Patient characteristics are summarized in Table 1. The study 152 
was approved by the Cantonal Research Ethics Board (STV 28-2006). All tumors were classified 153 
according to widely accepted diagnostic histologic criteria by two board certified pathologists, 154 
blinded to the clinicopathological outcome (M.D. and A.P.) (1). Validation of novel miRNAs 155 
was performed on 61 snap-frozen thyroid tissues (22 FVPTC, 24 PTC, 8 FTC, 2 hyperplastic 156 
nodules and 5 normal tissues) from surgically removed thyroid samples collected at the 157 
Department of Pathology, University of Pittsburgh Medical Center following the Institutional 158 
Review Board (IRB) approval. 159 
 160 
RNA Isolation. RNA was isolated from FFPE tissue samples using the RecoverAll kit (Ambion, 161 
Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. Each FFPE 162 
tissue specimen was stained with hematoxylin and eosin to ensure that characteristic features of 163 
the thyroid tumor were present. Areas with high density and purity (>80%) of tumor cells were 164 
marked for microdissection of adjacent sections to minimize contamination from surrounding 165 
healthy thyroid tissue or infiltrating cells. Overlapping areas in up to six adjacent slides were 166 
manually microdissected from 15 µm unstained histological sections under the guidance of a 167 
hematoxylin and eosin-stained slide using an Olympus SZ61 stereomicroscope (Olympus, 168 
Hamburg, Germany). RNA quality and quantity was assessed with a spectrophotometer 169 
(NanoDrop 1000, Thermo Scientific, USA). Total RNA was extracted from snap-frozen surgical 170 
specimens using Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA) as previously 171 
described (15). 172 
 173 
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miRNA Expression Analysis. Quantitation of mature miRNA expression levels in thyroid 174 
tumors and normal thyroid tissue was performed by RT-PCR using TaqMan® Human 175 
Microarray Arrays v3.0 (Applied Biosystems, Life Technologies, Carlsbad, CA) which was 176 
designed to detect 754 human miRNAs. The array was performed on an ABI 7900 platform 177 
(Applied Biosystems, Life Technologies, Carlsbad, CA).  First 150 ng of total RNA was reverse 178 
transcribed using a high-capacity cDNA archive kit (Applied Biosystems, Life Technologies, 179 
Carlsbad, Ca) and then followed by preamplification on an ABI 7500 Real-Time PCR System 180 
(Applied Biosystems, Life Technologies, Carlsbad, Ca). The following PCR was run on an ABI 181 
7900 Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad, CA). Out of 182 
three different endogenous controls (RNU44, RNU48, U6 snRNA), the two most stable ones 183 
were used for normalization of RNA input: RNU44 and U6 snRNA. Non-human miRNA ath-184 
miR159a was used as a negative control.  185 
 186 
MiRNA expression levels were calculated by relative quantitation using DataAssist v3.0 187 
software (Applied Biosystems, Life Technologies, Carlsbad, CA) and the fold-expression 188 
changes were determined by the 2
-ΔΔ
Ct method (16). Outliers among replicates were excluded 189 
and p-values were adjusted using Benjamini-Hochberg false discovery rate. The data are 190 
presented as the fold change of miRNA expression in tumors relative to normal thyroid tissues 191 
after normalization to endogenous controls. Maximum allowed Ct values were 38. Expression of 192 
individual miRNAs was analyzed using the TaqMan® individual miRNA assays (Applied 193 
Biosystems, Life Technologies, Carlsbad, CA) according to the manufacturer's instructions.  A 194 
RNA input of 10 ng for high-capacity cDNA archive kit (Applied Biosystems, Life 195 
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Technologies, Carlsbad, Ca) was reverse transcribed followed by amplification on an ABI 7500 196 
Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad, CA).  197 
 198 
Patient follow-up 199 
Complete follow-up data were collected using chart reports and the cancer registry of the canton 200 
Zürich and recorded as overall survival (OS), tumour-specific survival (TSS) and relapse-free 201 
survival (RFS). RFS was defined as the time between a patient’s thyroidectomy and tumor 202 
relapse after the first radioiodine therapy. 203 
 204 
Statistical analysis. Descriptive statistics, Mann-Whitney U test, Kaplan-Meier analysis and 205 
Cox regression was calculated with SPSS 21 (IBM, Armonk, NY, USA). Fold changes were 206 
calculated with Dataassyst v3.1 (Applied Biosystems, Life Technologies, Carlsbad, CA) as was 207 
the unsupervised hierarchical clustering.  208 
 209 
RESULTS 210 
Seventeen FVPTC, 27 classic PTC and 8 normal thyroid tissues were analyzed for expression of 211 
754 miRNAs using the most updated miRNA array panel which covers the complete Sanger 212 
Database v.14. Overall, some miRNAs were similarly expressed in FVPTC and classic PTC; 213 
however, the levels of miRNA expression were different between these tumor types and some 214 
miRNAs were uniqly dysregulated in FVPTC and classic PTC. The unsupervised hierarchical 215 
clustering analysis showed clear separation of the two entities from each other demonstrating 216 
individual clusters for FVPTC, PTC and normal thyroid tissue (Fig. 1) supporting their 217 
molecular and histopathologic differences.  218 
 Page 11 of 28 
Th
yr
oi
d
Co
m
pr
eh
en
siv
e 
m
ic
ro
RN
A
 e
xp
re
ss
io
n 
pr
of
ili
ng
 id
en
tif
ie
s n
ov
el
 m
ar
ke
rs
 in
 fo
lli
cu
la
r v
ar
ia
nt
 o
f p
ap
ill
ar
y 
th
yr
oi
d 
ca
rc
in
om
a.
 (d
oi:
 10
.10
89
/th
y.2
01
2.0
63
2)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
12 
 219 
Comparison of miRNA expression between FVPTC and classic PTC. We identified twenty-220 
one miRNAs significantly (p<0.05) deregulated (>2-fold up/down) in FVPTC as compared to 221 
normal tissue with 14 of these deregulated more than 5-fold up or down (Table 2). Strongly 222 
upregulated miRNAs in FVPTC were miR-146b-3p, -146-5p, -221, -222 and miR-222-5p, -181a 223 
which were previously reported in PTC (14, 17, 18). Interestingly, the level of expression for 224 
miR-146b-3p and miR-146b-5p was similar between FVPTC and classic PTC (30 to 33 fold for 225 
miR-146b-3p and 73 to 77 fold for miR-146b-5p respectively); however, expression of miR-221 226 
and miR-222-5p that are known to be upregulated in both PTC and FTC was twice higher in 227 
FVPTC as compared to classic PTC.  228 
 229 
We identified a number of downregulated miRNAs in both FVPTC and classic PTC including 230 
miR-1179, -138, -144-5p, -199b-5p, -204, -219-5p and miR-451 (Table 2). The levels of 231 
downregulation ranged between 3 and 54 fold. Four miRNAs were expressed significantly 232 
differently in FVPTC compared to classic PTC with a fold change more than 5 (miR-125a-3p, -233 
1271, -153, and -623) (Table 2).  234 
 235 
In addition, two novel miRNAs miR-375 and miR-551b were found to be highly upregulated in 236 
FVPTC. MiR-375 showed more than a 37-fold upregulation as compared to normal thyroid 237 
tissue and miR-551b was upregulated more than 22-fold (Table 2). Analysis of their expression 238 
in classic PTC also revealed their upregulation, but at a lower level (20-fold and 16-fold 239 
respectively). 240 
 241 
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Validation of miR-375 expression. miR-375 was highly upregulated in FVPTC but at a lower 242 
level in classic PTC using the array approach. To confirm array data and to determine whether 243 
miR-375 upregulation is specific for papillary carcinoma, we studied its expression in an 244 
independent set of 61 follicular cell derived neoplasms and normal thyroid tissue including 22 245 
FVPTC, 24 classic PTC, 8 FTC, 2 hyperplastic nodules and 5 normal tissues. In addition, we re-246 
analyzed all arrayed FVPTC and classic PTC samples for miR-375 expression using individual 247 
RT-PCR reactions. MiR-375 was strongly upregulated in FVPTC and classic PTC but not in 248 
FTC, HN or normal thyroid. A high correlation between array data and individual assays was 249 
observed (r=0.6). 250 
 251 
Correlation of miRNA expression with outcome in FVPTC patients. The up/downregulated 252 
miRNAs identified in all FVPTC samples were correlated with the survival data. Patients with an 253 
adverse clinical outcome, i.e. tumor relapse after first radioiodine therapy, distant metastases or 254 
tumor related death were compared to the control group. Because FVPTC are generally indolent 255 
neoplasms, overall survival (OS) is not a good clinical endpoint. Tumor-specific death (TSS) is a 256 
very rare event due to the low aggressiveness of these neoplasms and our study did not reach 257 
statistical power for this outcome. Recurrent tumor relapses impose a significant reduction in 258 
patient quality of life and therefore was used for outcome analysis. 259 
 260 
Upregulation of miR-181a-2-3p and of miR-99b-3p and downregulation of miR-222 were 261 
associated with a favorable outcome in terms of tumor relapse in FVPTC (p<0.05, Mann U test). 262 
In the first two, Kaplan Meier analysis reached statistical significance (p<0.05; Fig 2). Both 263 
miRNAs were confirmed in two separate multivariate Cox regression analyses including age, sex 264 
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14 
and tumor stage (miR-181a-2-3p (p<0.05; Exp(B) 0.136); miR-99b-3p; Exp(B) 0.170) the only 265 
parameters that reached statistical significance.  266 
 267 
DISCUSSION 268 
We assessed the miRNA expression in a large series of follicular variant and classic papillary 269 
thyroid carcinomas with the most comprehensive currently available miRNA coverage. We 270 
correlated miRNA expression with clinicopathological data and patient survival, revealing 271 
potential important prognostic markers for FVPTC. Finally, we reported a novel miRNA, miR-272 
375, which is extremely consistent and highly upregulated in FVPTC and PTC but not in 273 
follicular carcinomas, hyperplastic nodules and normal thyroid tissue. 274 
 275 
MiRNAs have been demonstrated to play important roles in a variety of fundamental cellular 276 
processes, including cell proliferation, differentiation, and cell death (10, 14). As a result, 277 
miRNAs are directly involved in the development and progression of cancer representing an 278 
important regulatory mechanism. In this study, we assess the miRNAome with the most 279 
comprehensive currently available coverage of Sanger miRBase v.14 in a large series of FVPTC 280 
samples.  281 
There are several well characterized miRNAs known to be upregulated (miR-146b, -21, -221, -282 
222) (14, 18, 19) and downregulated (miR-1, miR-138) (18, 20) in PTC. In the present work, we 283 
have confirmed these findings, which underline the robustness of this analysis and also 284 
strengthen the previously published work by ourselves and others. Interestingly, the level of 285 
expression for miR-146b-3p and miR-146b-5p was similar between FVPTC and classic PTC; 286 
however, expression of miR-221 and miR-222 that are known to be upregulated in both PTC and 287 
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15 
FTC was twice higher in FVPTC as compared to classic PTC. Potentially, this may be due to the 288 
fact that FVPTC share features of both classic PTC and FTC and miR-221 and miR-222 are 289 
important in regulation of both tumor types. In addition, we previously demonstrated a 290 
correlation between miRNA expression and the mutational status of PTC (14). We showed that 291 
both miR-221 and miR-222 were stronger upregulated in PTC with RAS mutations, which are 292 
commonly found in FVPTC. It would be potentially interesting to determine the prevalence of 293 
RAS mutations in this cohort and correlate it with miRNA expression.  294 
 295 
We identified several new, never before reported miRNAs being significantly upregulated in 296 
FVPTC and classic PTC. MiR-375 was upregulated more than 35-fold in FVPTC and at 20-fold 297 
in classic PTC and not found to be upregulated in normal thyroid tissue, hyperplastic nodules and 298 
follicular carcinomas. High level and PTC-specific upregulation may indicate a potential 299 
diagnostic utility for this miRNA. MiR-375 is known to play a role in other human malignancies 300 
including lung and breast cancer (12, 21, 22). Another miRNA found to be upregulated in both 301 
tumor types was miR-551b. However, this miRNA has never been shown to play a role in any 302 
human malignancy and therefore awaits confirmation in other studies and organ systems.  303 
 304 
PTC are known to be a heterogenous group of tumors, sharing in general a favourable outcome. 305 
Specific mutation profiles are found to be associated with distinct histological subtypes of PTC, 306 
such as the BRAF V600E mutations with a classic PTC phenotype, whereas RAS gene mutations 307 
and the BRAF K601E substitution are more frequently found in FVPTC (23, 24). The present 308 
study demonstrates that this is also true for miRNA expression. Overall, the miRNA profile 309 
demonstrated similar trends in expression between FVPTC and classic PTC. However, some 310 
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16 
miRNAs were uniquely dysregulated in FVPTC and classic PTC. For example, miR-125a-3p, -311 
1271 and -153 showed upregulation in FVPTC but were expressed at normal level or even 312 
downregulated in classic PTC, whereas the opposite pattern of expression was found for miR-313 
623. These miRNAs have never been reported in thyroid cancer but are known to be 314 
dysregulated in other human malignancies including esophageal, gastric, colon, hepatocellular, 315 
pancreas, breast cancer, neuroblastomas and leukemias (21, 25-36). The unsupervised 316 
hierarchical clustering analysis showed clear separation of the two types of PTC from each other 317 
demonstrating individual clusters for FVPTC and classic PTC, and supporting their molecular, 318 
histopathologic and clinical differences. 319 
 320 
FVPTC are known to have a favorable outcome. Identifying the small subset of patients who will 321 
suffer from recurrent disease is of major clinical interest. One of the important players in this 322 
scenario is the BRAF V600E mutation, which can be detected in about 40-45% of PTC (37), but 323 
at much lower frequency in FVPTC. Many studies demonstrated an association of this mutation 324 
with aggressive tumor behavior, although not all studies could confirm these findings (38). It is 325 
evident that a subset of tumors harbouring the BRAF V600E mutation still has a good prognosis, 326 
underscoring the need for new molecular markers. Recently, a correlation between deregulation 327 
of miRNA expression in miR-146b, -222, and -130b and aggressiveness of PTC was reported 328 
(20, 39). In this study, we were able to confirm upregulation of miR-222 and also identified 329 
novel markers of aggressiveness in FVPTC. Several miRNAs reached statistical significance 330 
when looking into RFS including miR-181a-2-3p, -222, and -99b-3p. The Kaplan Meier survival 331 
analysis was able to confirm a significant result for miR-181a-2-3p and miR-99b-3p. Patients 332 
had an adverse outcome if miR-222 was expressed at a higher level and miR-181a-2-3p and 333 
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17 
miR-99b-3p were expressed at a lower level and as compared to normal thyroid tissue. A 334 
multivariate analysis including age, sex and tumor stage showed that the two latter miRNAs 335 
were the only significant parameters, predicting patient relapse. MiR-181a-2-3p has not been 336 
reported in human cancer before, but miR-99b-3p has been linked to prostate cancer (40, 41). 337 
Although further studies are needed to to confirm this finding in a larger cohort of patients, these 338 
miRNAs bear the potential to serve as good molecular markers helping to stratify patients better 339 
in the future and facilitate guiding appropriate clinical management.  340 
 341 
In conclusion, we are reporting a comprehensive miRNA profile of FVPTC, the most common 342 
histologic type of PTC. We discovered a new miRNA (miR-375) that is upregulated in FVPTC 343 
and classic PTC, and identified several miRNAs that can predict patient relapse free survival. 344 
Further studies will have to prove their potential diagnostic and predictive clinical value. 345 
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 487 
 488 
Figure 1: Unsupervised hierarchical clustering (distance measure: Euklidian Distance, Clustering 489 
method: complete linkage) of all reported miRNAs. Follicular variant of papillary thyroid 490 
carcinoma (FVPTC), classic papillary thyroid carcinoma (PTC) and normal thyroid tissue form 491 
three distinct clusters.   492 
 493 
494 
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 496 
Figure 2: Kaplan Meier survival plots: Relapse free survival (RFS) is reduced for all three shown 497 
miRNAs, but only miR-181a-2-3p and miR-99b reach statistical significance (log rank p<0.002 498 
and p<0.018).  499 
500 
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Tables: 501 
Table 1: Patients characteristics 502 
  
 
Classic PTC FVPTC Total 
Sex (n) female 18 10 28 
male 9 7 16 
Age (years) 
years±SE 
Mean 
47.8±3 50.9±4.3 49±3 
pT pT1 4 1 5 
pT2 3 0 3 
pT3 20 15 35 
pT4 0 1 1 
Status OS 
(n) 
censored 24 13 37 
death 3 4 7 
t follow-up 
OS (months) 
 74.6±47 80.8±47.4 77±46.7 
Status TSS 
(n) 
censored 25 16 41 
death 2 1 3 
t follow-up 
TSS 
(months) 
 74.6±47 80.8±47.4 77±46.7 
Status 
Relapse (n) 
censored 8 8 16 
relapse 19 9 28 
t follow-up 
RFS 
(months) 
 25.7±29.6 55.9±54 37.4±42.8 
Total (n) 27 17 44 
OS: overall survival; TSS: tumor-specific survival; RFS: relapse-free survival 503 
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Table 2. Fold changes and p-values of significant deregulated miRNAs. 
miRNA 
FVPTC vs. NT 
Fold change >2 
(p<0.05) 
FVPTC vs. NT 
Fold change >5 
(p<0.05) 
FVPTC vs. PTC 
Fold change >5 
(p<0.05) 
FVPTC 
(RQ) 
FVPTC 
(P-Value) 
Classic PTC 
(RQ) 
Classic PTC 
(P-Value) 
hsa-let-7i-3p X 
  
3.2283 0.0138 1.9262 0.1875 
hsa-miR-1179 X X 
 
0.0928 0.0269 0.0291 0.0007 
hsa-miR-125a-3p 
  
X 12.5594 0.075 1.1127 0.9453 
hsa-miR-1271 
  
X 2.8553 0.3094 0.4106 0.4034 
hsa-miR-138 X X 
 
0.1564 0.0091 0.2647 0.0013 
hsa-miR-144-5p X 
  
0.2472 0.0143 0.1392 0.0004 
hsa-miR-146b-3p X X 
 
29.4838 0.0143 32.8455 0.0138 
hsa-miR-146b-5p X X 
 
77.1832 0 73.2796 0.0002 
hsa-miR-153 
  
X 2.7257 
 
0.1184 
 hsa-miR-15a-3p X 
  
3.8019 0.0138 3.3222 0.0148 
hsa-miR-181a-2-3p X X 
 
6.2228 0.0039 3.3402 0.0253 
hsa-miR-204 X X 
 
0.1209 0.0053 0.058 0 
hsa-miR-21 X 
  
4.1654 0.0085 4.9069 0.0009 
hsa-miR-219-5p X X 
 
0.0372 0.0121 0.0185 0.0305 
hsa-miR-221 X X 
 
16.1265 0 7.2353 0.0004 
hsa-miR-222 X X 
 
16.2601 0.0003 13.5943 0.0008 
hsa-miR-222-5p X X 
 
9.7092 0.0138 3.396 0.1571 
hsa-miR-34a X 
  
3.285 0.0137 3.05 0.0022 
hsa-miR-34a-3p X 
  
2.5873 0.043 1.8738 0.0588 
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28 
hsa-miR-375 X X 
 
37.094 0.0003 20.1274 0.0009 
hsa-miR-451 X 
  
0.3051 0.0252 0.1747 0.0004 
hsa-miR-542-5p X X 
 
7.2879 0.0185 2.1064 0.4096 
hsa-miR-551b X X 
 
22.5078 0.0138 15.7151 0.0166 
hsa-miR-623 
  
X 0.4794 0.7667 2.3888 0.6962 
hsa-miR-99b-3p X X 
 
7.0874 0.0509 1.3553 0.8164 
FVPTC-follicular variant, papillary thyroid carcinoma, PTC- classic papillary thyroid carcinoma, NT-normal thyroid; X-miRNAs with 
significant difference in expression between studied tissues (PTC, FVPTC and NT). 
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